Partners In Practice Articles

New Location in Orchard Park

Beginning in August 2019, the Roswell Park Care Network Southtowns medical oncology/hematology practice will move to 3041 Orchard Park Road in Orchard Park.

Survivorship Program Broadens Services

There are 128,000 cancer survivors in Western New York and many of these individuals must continue their surveillance after they have received a clean bill of health.

Improving Care Delivery Through Technology

Roswell Park Comprehensive Cancer Center is growing, and with that growth we’ve had to make many internal changes to meet the expectations of your patients. We’ve added services, crucial support staff and expertise in key areas.

Cytoreduction/HIPEC in Gastric Cancer: Who benefits, and when to consider it?

Gastric adenocarcinoma commonly spreads through carcinomatosis or peritoneal metastases (PM). This was often discovered at the time of attempted curative gastric resection, given the poor ability of preoperative staging CT scans to detect the presence and extent of PM. In patients where visible PMs are absent, diagnostic laparoscopy with peritoneal lavage and cytology has been shown to be an effective method of noting free intraperitoneal tumor cells. This is also defined as M1 disease and is generally associated with T3 or T4 primary gastric cancers.

Evolving Surgical Approaches to Treating Advanced Gastric Cancer

There has been significant debate over the use of minimally invasive resection for the management of advanced gastric cancer. Laparoscopic surgery appears as a favorable approach, given the previously reported decrease in postoperative pain, pulmonary complications, and hospital lengths of stay. The reluctance to widely adopt this technique centers on concerns about its oncologic completeness and the complexity of the procedure.

Advances in Treatment of Neuroendocrine Cancers

To prepare for the second annual Roswell Park Comprehensive Cancer Center patient seminar on neuroendocrine cancer on October 18, 2014, I sat down to think about the progress made in this field.

Selecting the Optimal Liver-Directed Therapy for NETs

Neuroendocrine tumors (NET) are a group of relatively slow-growing tumors that arise mostly in the pulmonary and gastrointestinal system. Considered rare, their incidence has increased 6.3% in the last 25 years, with a prevalence of 35 per 100,000 patients. Because patients with these tumors generally present with vague symptoms, the diagnosis is often delayed by five to seven years.